Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCAQ) Head to Head Comparison

Genocea Biosciences (NASDAQ:GNCAQ) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Risk & Volatility

Genocea Biosciences has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Genocea Biosciences and Inhibikase Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	0.00
Inhibikase Therapeutics	0	1	1	0	2.50

Inhibikase Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 327.63%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Genocea Biosciences.

Insider & Institutional Ownership

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Genocea Biosciences and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Inhibikase Therapeutics	N/A	-350.63%	-201.82%

Earnings & Valuation

This table compares Genocea Biosciences and Inhibikase Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Inhibikase Therapeutics	N/A	N/A	-$19.03 million	($2.67)	-0.57

Summary

Inhibikase Therapeutics beats Genocea Biosciences on 5 of the 8 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.